July 7 (Reuters) - Amgen Inc:
* Denosumab demonstrates superiority over Zometa(R) in pivotal Phase 3
head-to-head trial in breast cancer patients with bone metastases
* Says first of three pivotal oncology trials meets primary and secondary
endpoints
* Says both results were statistically significant
* Says there was no statistically significant difference in the rate of onj
between the two treatment arms
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Denosumab demonstrates superiority over Zometa(R) in pivotal Phase 3
head-to-head trial in breast cancer patients with bone metastases
* Says first of three pivotal oncology trials meets primary and secondary
endpoints
* Says both results were statistically significant
* Says there was no statistically significant difference in the rate of onj
between the two treatment arms
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.